Vivos Inc. (RDGL)
Oxford Ledge is still expanding full research coverage of RDGL. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Vivos develops yttrium-90 based precision radionuclide therapy devices for treating cancers in humans and animals.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 10-K Annual financial report with audited statements 2026-03-31
- 10-Q Quarterly financial report (unaudited) 2025-11-12
- 8-K Entry into material agreement; Departure/election of directors or officers; Financial statements and exhibits 2025-09-22
- 8-K Other material event 2025-09-18
Source: SEC EDGAR.
Annual results
5 years of annual figures for RDGL, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $68,379 | -$3.1M | -$0.01 |
| 2024 | $27,995 | -$2.9M | -$0.01 |
| 2023 | $19,500 | -$2.9M | -$0.01 |
| 2022 | $36,499 | -$2.5M | -$0.01 |
| 2021 | $14,887 | -$2.5M | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for RDGL. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open RDGL in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.